natgillin/translations-raw huggingface dataset:
One patient received a single dose of 16.4 mg/kg and the other patient received a single dose of 17.3 mg/kg.
En bolnik je dobil en sam odmerek 16,4 mg/kg, drugi bolnik pa en sam odmerek 17,3 mg/kg.
• If you are allergic (hypersensitive) to cidofovir or any of the other ingredients of Vistide.
• Če ste alergični (preobčutljivi) na cidofovir ali katerokoli sestavino zdravila Vistide.
These side effects usually disappear when treatment with Vistide is stopped.
Ti neželeni učinki ponavadi izginejo, ko se zdravljenje z zdravilom Vistide konča.
• CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
• POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, PREDPISANI IMETNIKU Izdaja zdravila je le pod omejenimi pogoji in na recept (glejte Dodatek I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
In study GS-93-107 conducted in patients who had relapsed after treatment with other agents, the median time to retinitis progression was 115 days.
V študiji GS-93-107, opravljeni pri bolnikih z relapsom po zdravljenju z drugimi zdravili, je bil mediani čas do napredovanja retinitisa 115 dni.
Vistide may cause short-term side effects such as fatigue or weakness.
Zdravilo Vistide lahko povzroči kratkotrajne neželene učinke, npr. utrujenost in šibkost.
Vistide should be infused only into veins with adequate blood flow to permit rapid dilution and distribution.
Infundirati se ga sme samo v vene, v katerih je pretok krvi dovolj velik, da omogoča hitro raztopitev in porazdelitev.
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
For storage conditions of the diluted medicinal product, see section 6.3.
Za pogoje shranjevanja raztopljenega zdravila glejte poglavje 6.3.
Each pack contains one 5 ml vial.
Eno pakiranje vsebuje eno 5 ml vialo.
Other Cidofovir should be considered a potential carcinogen in humans (see section 5.3).
Drugo Cidofovir je treba obravnavati kot potencialen kancerogen za človeka (glejte poglavje 5.3).
These medicines must be stopped at least 7 days before taking Vistide.
Zdravljenje s temi zdravili je treba opustiti vsaj 7 dni pred začetkom zdravljenja z zdravilom Vistide.
One of these patients experienced a minor transient change in renal function, while the other patient had no change in renal function (see section 4.4).
Pri enem od teh bolnikov je prišlo do majhne prehodne spremembe v delovanju ledvic, pri drugem pa se delovanje ledvic ni spremenilo (glejte poglavje 4.4).
Other types of IV set tubing and infusion bags have not been studied.
Druge vrste intravenskih cevnih kompletov in infuzijskih vrečk niso raziskane.
• Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription, as these may interact with
• Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta, saj lahko pride do medsebojnega delovanja z zdravilom Vistide ali probenecidom.
These include: • tenofovir containing medicines, used to treat HIV-1 infection and/or chronic hepatitis B
Ta vključujejo: • zdravila, ki vsebujejo tenofovir, ki se uporabljajo za zdravljenje okužb z virusom HIV-1 in/ali
Vistide must be administered by a healthcare professional (doctor or nurse) in a hospital setting.
Zdravilo Vistide vam mora dati zdravstveni delavec (zdravnik ali medicinska sestra) v bolnišnici.
Starting (induction) treatment
Začetno (uvajalno) zdravljenje
Like all medicines, Vistide can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Vistide neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Do not use Vistide
Ne uporabljajte zdravila Vistide
Suspension of maintenance treatment with cidofovir should be considered in accordance with local recommendations for the management of HIV infected patients.
Prenehanje vzdrževalnega zdravljenja s cidofovirom mora biti usklajeno z lokalnimi priporočili za vodenje bolnikov, okuženih s HIV.
Probenecid is not supplied with Vistide and should be obtained via the Marketing Authorisation Holder of probenecid.
Probenecid ni dobavljen skupaj z zdravilom Vistide in ga je treba dobiti od imetnika dovoljenja za promet s probenecidom.
Reductions in blood cell and platelet counts have also occurred.
Prišlo je tudi do znižanja števila vseh krvnih celic ter krvnih ploščic.
At the end of this leaflet, there is further information for healthcare professionals on how to administer Vistide.
Ob koncu teh navodil so dodatne informacije za zdravstvene delavce za dajanje zdravila Vistide.
• Probenecid may interact with other medicines commonly used in the treatment of AIDS and AIDS-related illnesses, such as zidovudine (AZT).
• Probenecid ima lahko medsebojne učinke z drugimi zdravili, ki se pogosto uporabljajo za zdravljenje AIDS-a in z AIDS-om povezanih bolezni, npr. z zidovudinom (AZT).
The safety and efficacy of Vistide have not been established in patients with hepatic disease and therefore it should be used with caution in this patient population.
Varnost in učinkovitost zdravila Vistide pri bolnikih z boleznijo jeter nista bili dokazani, zato ga je treba pri tej populaciji bolnikov uporabljati previdno.
If visible particles or discolouration are observed, the vial should not be used.
Če so opazni vidni delci ali obarvanje, se takšne viale ne sme uporabiti.
Use of cidofovir without concomitant probenecid has not been clinically investigated.
Uporaba cidofovira brez sočasne uporabe probenecida klinično ni raziskana.
If you can tolerate the additional fluid load, your doctor may administer a second litre of fluid.
Če prenesete dodatno obremenitev s tekočino, vam zdravnik lahko da še drugi liter tekočine.
The safety and efficacy of Vistide in children below 18 years of age have not been established.
Varnost in učinkovitost zdravila Vistide pri otrocih, mlajših od 18 let nista bili dokazani.
• aminoglycosides, pentamidine or vancomycin (for bacterial infections)
• aminoglikozide, pentamidin ali vankomicin (za bakterijske okužbe)
It must not be administered by other methods including intraocular injection (direct injection into the eye) or topically (on the skin).
Ne sme se ga dati na drugačen način, vključno z intraokularnim injiciranjem (injicirati neposredno v oko) ali zunanje (na kožo).
Probenecid is only taken on the same day that Vistide is given.
Probenecid se vzame samo na isti dan, kot se da zdravilo Vistide.
MARKETING AUTHORISATION NUMBER(S) EU/1/97/037/001
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/97/037/001
The formulation is pH-adjusted with sodium hydroxide (and hydrochloric acid if needed) and contains no preservatives.
Pripravek ima pH uravnan z natrijevim hidroksidom (in klorovodikovo kislino, če je potrebno) in ne vsebuje konzervansov.
Do not use Vistide after the expiry date which is stated on the label.
Zdravila Vistide ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Direct intraocular injection of Vistide is contraindicated; direct injection may be associated with significant decreases in intraocular pressure and impairment of vision.
Neposredno intraokularno injiciranje zdravila Vistide je kontraindicirano; neposredno injiciranje lahko spremljata pomembno znižanje očesnega tlaka in okvara vida.
• If you cannot take the medicine probenecid because of a serious allergy to probenecid or other sulfa-containing medicines (e.g. sulfamethoxazole).
• Če ne morete jemati zdravila probenecid, ker imate resno alergijo na probenecid ali druga zdravila, ki vsebujejo žveplo (npr. sulfametoksazol).
1 vial 375 mg/5 ml
1 viala 375 mg/5 ml
• The potential for interactions between Vistide and anti-HIV protease inhibitors has not been studied.
• Možni medsebojni učinki med zdravilom Vistide in zaviralci proteaz proti HIV niso raziskani.
For those patients who fully recover from cidofovir associated renal toxicity, the benefits-risk balance of reintroducing cidofovir has not yet been evaluated.
Za tiste bolnike, ki popolnoma okrevajo po okvari ledvic, ki jo je povzročil cidofovir, razmerje med koristjo in tveganji pri ponovni uvedbi cidofovira še ni raziskano.
In both cases, the overdose occurred during the first induction dose and no additional cidofovir therapy was administered.
V obeh primerih je do prevelikega odmerjanja prišlo med prvim začetnim odmerkom in nadaljnja terapija s cidofovirom ni bila uporabljena.
Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2 - 8ºC when dilution is performed under controlled and validated aseptic conditions.
Kemična in fizikalna stabilnost med uporabo sta dokazani za 24 ur pri temperaturi od 2-8°C, če je bila raztopitev izvedena pod kontroliranimi in validiranimi aseptičnimi pogoji.
Your doctor may also instruct you to drink plenty of fluids.
Zdravnik vam bo morda tudi naročil, da pijte veliko tekočin.
• During treatment with Vistide you should receive regular follow-up eye examinations for possible eye irritation, inflammation or swelling.
• Med zdravljenjem z zdravilom Vistide morate redno opravljati preglede oči zaradi morebitnega draženja, vnetja ali otekanja oči.
Sodium hydroxide Hydrochloric acid Water for injections
natrijev hidroksid klorovodikova kislina voda za injekcije
The recommended dose, frequency of use, or rate of infusion must not be exceeded.
Ne sme se preseči priporočenega odmerka, pogostnosti uporabe in hitrosti infundiranja.
Vistide should be used only when other agents are considered unsuitable.
Zdravilo Vistide naj bi uporabljali le, če druga zdravila niso primerna.
Vistide is formulated for intravenous infusion only and must not be administered by other methods including intraocular injection or topically.
Zdravilo Vistide je formulirano samo za intravensko infundiranje in se ne sme uporabljati na noben drugačen način, vključno z intraokularnim injiciranjem ali zunanje.
Nausea, vomiting
Navzea, bruhanje
The major route of elimination of cidofovir was by renal excretion of unchanged drug by a combination of glomerular filtration and tubular secretion.
Glavna pot izločanja cidofovira je bilo ledvično izločanje nespremenjenega zdravila s kombinacijo glomerulne filtracije in tubulne sekrecije.
Vistide will not stop you passing HIV infection onto other people so you should continue to take precautions to avoid infecting
Zdravilo Vistidine ne bo preprečilo prenosa okužbe na druge ljudi, zato morate nadaljevati z ustreznimi previdnostnimi ukrepi, da ne okužite drugih.
If you drive or operate machinery, discuss this with your doctor to get their advice about stopping these activities based upon your disease and your tolerance of the medicine.
Če vozite ali upravljate s stroji, se posvetujte z zdravnikom o prekinitvi dejavnosti glede na vašo bolezen in vaše prenašanje zdravila.
However, in case of difficulty in obtaining probenecid the local representative of the Marketing Authorisation Holder of Vistide should be contacted for information (see also sections 4.2 and 4.4).
V primeru težav z dobavo probenecida pa se je mogoče za informacije obrniti na lokalnega predstavnika imetnika dovoljenja za promet z zdravilom Vistide (glejte tudi poglavji 4.2 in 4.4).
What Vistide looks like and contents of the pack
Izgled zdravila Vistide in vsebina pakiranja
Iritis, uveitis, hypotony of the eye (see section 4.4)
Iritis, uveitis, hipotonija očesa (glejte poglavje 4.4)
Cases of acute renal failure have been reported after only one or two doses of cidofovir.
Opisani so primeri akutne odpovedi ledvic po le enem ali dveh odmerkih cidofovirja.
There have been reports of reduced white blood counts, liver toxicity, kidney toxicity and destruction of red blood cells.
Poročali so o znižanem številu belih krvnih celic, jetrni toksičnosti, ledvični toksičnosti in propadu rdečih krvnih celic.
Blood and lymphatic system disorders Very common
Bolezni krvi in limfatičnega sistema Zelo pogosti
Maintenance treatment.
Vzdrževalno zdravljenje.
Proteinuria appears to be an early and sensitive indicator of cidofovir-induced nephrotoxicity.
Kaže, da je proteinurija zgoden in občutljiv kazalec nefrotoksičnih učinkov cidofovira.
There are no data from the use of cidofovir in pregnant women.
Podatkov o uporabi cidofovira pri nosečnicah ni.
If you are taking zidovudine, you should discuss with your doctor whether to temporarily stop taking zidovudine or decrease the dose of zidovudine by 50% on days when Vistide and probenecid are given.
Če jemljete zidovudin, se morate z zdravnikom posvetovati, ali naj začasno prekinete uporabo zidovudina ali pa ob dneh, ko dobite zdravilo Vistide in probenecid, zmanjšate odmerek zidovudina za 50%.
It is recommended to discontinue potentially nephrotoxic agents at least 7 days before starting cidofovir.
Zdravljenje s potencialno nefrotoksičnimi sredstvi je priporočljivo opustiti vsaj 7 dni pred začetkom zdravljenja s cidofovirom.
Not known
Neznano
CMV attacks the retina of the eye and may cause loss of vision, and eventually lead to blindness.
CMV napade očesno mrežnico in lahko povzroči poslabšanje vida in končno tudi s slepoto.
Refrigerated infusion bags should be allowed to warm to room temperature prior to use.
Ohlajene infuzijske vrečke je treba pustiti, da se pred uporabo ogrejejo na sobno temperaturo.
Peri- and post-natal development studies in which female rats received subcutaneous injections of cidofovir once daily at doses up to 1.0 mg/kg/day from day 7 of gestation through day 21 postpartum (approximately 5 weeks) resulted in no adverse effects on viability, growth, behaviour, sexual maturation or reproductive capacity in the offspring.
Peri- in postnatalne razvojne študije, v katerih so podganje samice enkrat na dan dobivale subkutane injekcije cidofovira v odmerkih do 1,0 mg/kg/dan, in sicer od 7. dne gestacije do 21. postpartalnega dneva (približno 5 tednov), niso pokazale nobenih neželenih učinkov na sposobnost za življenje mladičev, njihovo rast, vedenje, spolno dozorevanje ali reprodukcijsko zmožnost.
Patients receiving both drugs should be closely monitored for zidovudine induced haematological toxicity.
Bolnike, ki jemljejo obe zdravili, je treba skrbno opazovati glede hematološke toksičnosti, ki jo povzroča zidovodin.
Adverse reactions possibly or probably related to cidofovir based on clinical trial experience and post-marketing surveillance
Neželeni učinki, morda ali verjetno povezani s cidofovirjem na podlagi kliničnih preskušanj in pomarketinškega spremljanja
Cidofovir diphosphate inhibits these viral polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerases alpha, beta, and gamma.
Cidofovirdifosfat zavre te virusne polimeraze v koncentracijah, ki so od 8- do 600-krat nižje od koncentracij, potrebnih za zavrtje DNA polimeraz alfa, beta in gama v človeških celicah.
Renal insufficiency [creatinine clearance ≤ 55 ml/min or ≥ 2+ proteinuria (≥ 100 mg/dl)] is a contraindication for the use of Vistide (see sections 4.3 and 4.4).
Ledvična insuficienca [očistek kreatinina ≤ 55 ml/min ali proteinurija ≥ 2+ (≥ 100 mg/dl)] je kontraindikacija za uporabo zdravila Vistide (glejte poglavji 4.3 in 4.4).
If Vistide contacts the skin, wash membranes and flush thoroughly with water.
Če pride zdravilo Vistide v stik s kožo, jo je treba umiti in temeljito splakniti z vodo.
The therapy should be prescribed by a physician experienced in the management of HIV infection.
Zdravljenje mora predpisati zdravnik, ki ima izkušnje z vodenjem okužbe s HIV.
Vistide will not cure CMV retinitis but may improve your condition by delaying progression of the disease.
Zdravilo Vistide citomegalovirusnega retinitisa ne ozdravi, lahko pa izboljša stanje, ker upočasni napredovanje bolezni.
If you have accidentally been given more Vistide than prescribed for you, tell your doctor immediately.
Če ste pomotoma prejeli večji odmerek zdravila Vistide, kot vam je bil predpisan, to nemudoma povejte zdravniku.
Allergic reactions, with skin inflammation, itching, hives and, rarely, severe allergic reactions, and serious skin reaction have occurred.
Prišlo je do alergijskih reakcij z vnetjem kože, srbenjem in koprivnico; redko je prišlo tudi do hudih alergijskih reakcij in hudih kožnih reakcij.
Therefore before giving you probenecid your doctor should consult the current prescribing information regarding the safety of probenecid.
Preden vam predpiše probenecid, mora vaš zdravnik za dodatne podatke o varnosti preveriti veljavne informacije o varnosti probenecida.
At the 4 cidofovir levels (12.5 to 100 µg/ml) tested, the percentage of damaged metaphases and number of aberrations per cell increased in a concentrationdependent manner.
Pri 4 raziskanih koncentracijah cidofovira (od 12,5 do 100 µg/ml) sta odstotek okvarjenih metafaz in število aberacij na celico naraščala od koncentracije odvisno.
Women of childbearing potential have to use effective contraception during and after treatment with cidofovir.
Ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem s cidofovirom in po njem.
Renal insufficiency/Haemodialysis
Insuficienca ledvic/hemodializa
The in vitro sensitivity to cidofovir is shown in the following table:
Občutljivost za cidofovir in vitro prikazuje naslednja preglednica:
In vitro protein binding
Vezava na beljakovine in vitro
Patients receiving cidofovir must have their serum creatinine and urine protein levels determined on specimens obtained within 24 hours prior to the administration of each dose of cidofovir.
Pri bolnikih, ki dobivajo cidofovir, je treba koncentracijo kreatinina v serumu in beljakovin v urinu določiti v vzorcih, dobljenih v 24 urah pred vsakim odmerkom cidofovira.
How to take probenecid with Vistide
Kako jemati probenecid z zdravilom Vistide
Vistide must be given by a doctor or nurse with appropriate experience in treating people with AIDS.
Zdravilo Vistide mora dati zdravnik ali medicinska sestra z ustreznimi izkušnjami v zdravljenju bolnikov z AIDS-om.
It is unknown whether cidofovir/metabolites are excreted in human milk.
Ni znano, ali se cidofovir/presnovki izločajo v materino mleko.
High flux haemodialysis has been shown to reduce the serum levels of cidofovir by approximately 75%.
Dokazano je, da visokopretočna hemodializa zmanjša koncentracijo cidofovira v serumu za približno 75%.
All clinical trials relevant to clinical efficacy evaluation were performed using probenecid concomitantly with cidofovir.
V vseh kliničnih preizkušanjih, pomembnih za oceno klinične učinkovitosti, so sočasno s cidofovirom uporabljali probenecid.
In vitro protein binding of cidofovir to plasma or serum protein was 10% or less over the cidofovir concentration range 0.25 to 25 µg/ml.
Vezava cidofovira na beljakovine v plazmi ali serumu in vitro je bila v koncentracijskem območju od 0,25 do 25 µg/ml cidofovira 10% ali manj.
Treatment with Vistide must not be initiated in patients with creatinine clearance ≤ 55 ml/min, or ≥ 2+ proteinuria (≥ 100 mg/dl), as the optimum induction and maintenance doses for patients with moderate to severe renal impairment are not known.
Zdravljenja z zdravilom Vistide se ne sme začeti pri bolnikih, ki imajo očistek kreatinina ≤ 55 ml/min ali proteinurijo ≥ 2+ (≥ 100 mg/dl), ker optimalni začetni in vzdrževalni odmerki za bolnike z zmerno do hudo okvaro ledvic niso znani.
If you become pregnant while receiving this medication, you must inform your doctor immediately.
Če zanosite med uporabo tega zdravila, morate nemudoma obvestiti zdravnika.
See the package leaflet for further information.
Za nadaljne informacije glejte navodilo za uporabo.
Probenecid tablets are given to lower the risk of kidney damage.
Tablete probenecida se uporabljajo za zmanjšanje tveganja okvare ledvic.
In patients exhibiting ≥ 2+ proteinuria, intravenous hydration should be performed and the test repeated.
Pri bolnikih s proteinurijo ≥ 2+ je treba opraviti intravensko hidracijo in preiskavo ponoviti.
Refrigerated solutions should be allowed to warm to room temperature prior to use.
Ohlajeno raztopino je treba pustiti, da se pred uporabo ogreje na sobno temperaturo.
In patients with normal renal function, 80 to 100% of the intravenous dose was recovered in the urine over 24 hours as unchanged cidofovir.
Pri bolnikih z normalnim delovanjem ledvic se je v 24 urah od 80 do 100-odstotnega intravenskega odmerka izločilo v urinu kot nespremenjeni cidofovir.
Patients receiving cidofovir should be advised to have regular follow-up ophthalmologic examinations for possible occurrence of uveitis/iritis and ocular hypotony.
Bolnikom, ki dobivajo cidofovir, je treba svetovati, naj redno opravljajo oftalmološke preglede zaradi morebitnega pojava uveitisa/iritisa in očesne hipotonije.
To reduce the risk of kidney damage, you will receive intravenous fluids (normal saline) before each dose of Vistide and probenecid tablets before and after each dose of Vistide (see section 3 below for more information).
Da bi zmanjšali tveganje za okvaro ledvic, boste dobili intravensko tekočino (fiziološko raztopino) pred vsakim odmerkom zdravila Vistide in tablete probenecida pred in po vsakem odmerku zdravila Vistide (glejte poglavje 3 spodaj za več informacij).
Should not be administered by intraocular injection.
Ne sme se uporabljati za intraokularno injiciranje.
The safety of cidofovir has not been evaluated in patients receiving other known potentially nephrotoxic agents (e.g. tenofovir, aminoglycosides, amphotericin B, foscarnet, intravenous pentamidine, adefovir and vancomycin).
Varnost cidofovira ni ugotovljena pri bolnikih, ki dobivajo druge potencialno nefrotoksične učinkovine (npr. tenofovir, aminoglikozide, amfotericin B, foskarnet, intravenski pentamidin, adefovir in vankomicin).
Probenecid may also cause other side effects including loss of appetite, sore gums, flushing, hair loss, dizziness, reduced red blood cell count and increased frequency of passing water (urinating).
Probenecid lahko povzroči tudi druge neželene učinke, kot so izguba apetita, boleče dlesni, zardevanje, izpadanje las, omotica, znižano število rdečih krvnih celic in večja pogostost odvajanja vode (uriniranja).
5 ml clear glass vials with a 5 ml nominal fill volume.
5 ml viale iz prozornega stekla za enkratno uporabo, s 5 ml nominalnega polnilnega volumna.
Hypersensitivity reactions, with dermatitis, pruritus, urticaria and, rarely, anaphylaxis, and Stevens-Johnson syndrome have occurred.
Pojavile so se preobčutljivostne reakcije z dermatitisom, srbenjem, urtikarijo in, redko, anafilaksijo in Stevens-Johnsonovim sindromom.
Two cases of cidofovir overdose have been reported.
Opisana sta dva primera prevelikega odmerjanja cidofovira.
Preclinical animal studies demonstrated that nephrotoxicity was the major dose-limiting toxicity of cidofovir.
Predklinične študije na živalih so pokazale, da so nefrotoksični učinki glavni toksični pojavi, ki omejujejo odmerek cidofovira.
Probenecid is known to increase the exposure of many substances (e.g., paracetamol, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicyclic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
Znano je, da probenecid zveča izpostavljenost številnim zdravilom (npr. paracetamolu, acikloviru, zaviralcem angiotenzinske konvertaze, aminosalicilni kislini, barbituratom, benzodiazepinom, bumetanidu, klofibratu, metotreksatu, famotidinu, furosemidu, nesteroidnim protivnetnim zdravilom, teofilinu in zidovudinu).
The preparation of Vistide diluted solution should be done in a laminar flow biological safety cabinet.
Raztopino zdravila Vistide je treba pripraviti v biološkem varnostnem sistemu z laminarnim pretokom.
Cidofovir enters cells by fluid-phase endocytosis and is phosphorylated to cidofovir monophosphate and subsequently to cidofovir diphosphate.
Cidofovir vstopi v celice z endocitozo tekoče faze ter se fosforilira v cidofovirmonofosfat in nato v cidofovirdifosfat.